About 100 reports

  • Beijing Minhai Biotechnology Co Ltd
  • Research and Development Brief

Similarly, the Universities" portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises ##, ##, ## and ## molecules, respectively.

  • Gastrointestinal Drug
  • Infectious Disease
  • China
  • World
  • Product Initiative
  • Opioid-Induced Constipation (OIC) - Companies Involved in Therapeutics Development
  • GI INFLAMMATION VIA A CYCLIC GMP MEDIATED MECHANISM TO DOWNREGULATE IKK AND NF-KAPPAB."

These medicines affect the gastrointestinal tract in a variety of ways.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Opioid
  • United States
  • Product Initiative
  • Clinical Trial profile. 336 Trial Title
  • Official Title

The prominent features of this report are - ##.

  • Gastrointestinal Drug
  • Hospital
  • Therapy
  • World
  • Product Initiative
  • NARONAPRIDE - DRUG PROFILE
  • RQ-00000774 - DRUG PROFILE

Patients were randomly assigned to one of two arms - one arm received Insegia alone, the other arm received placebo.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • Product Initiative
  • RaQualia Pharma Inc.
  • FEATURED NEWS & PRESS RELEASES
  • FEATURED NEWS & PRESS RELEASES

IBS is one of the most common gastrointestinal disorders.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • Company Operations
  • RedHill Biopharma Ltd.
  • ALLERGAN PLC
  • PRODUCTS UNDER DEVELOPMENT BY UNIVERSITIES/INSTITUTES, H1 2018

IBS is one of the most common gastrointestinal disorders iii.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Product Initiative
  • REDHILL BIOPHARMA LTD
  • SCY-002P - DRUG PROFILE

IBS is one of the most common gastrointestinal disorders##.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Product Initiative

Colace®Capsules is the number one doctor recommended stool softener brand.

  • Gastrointestinal Drug
  • Healthcare
  • Pharmaceutical
  • United States
  • Purdue Pharma L.P.
  • RECCE LTD
  • RDX-023 - DRUG PROFILE

IBS is one of the most common gastrointestinal disorders.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • Company
  • Product Initiative

These efforts are being led by Dr Mark Pimentel, director of the gastrointestinal motility program at Cedars-Sinai Medical Center.

  • Gastrointestinal Drug
  • Therapy
  • United States
  • Company
  • Synthetic Biologics
  • MAY 02, 2001: ASTRAZENECA RECEIVES SIX MONTHS' MARKET EXCLUSIVITY FOR PRILOSEC
  • OCT 20, 2000: JOINT FDA ADVISORY COMMITTEE CONFIRMS OTC PRILOSEC (OMEPRAZOLE) SAFETY AND EFFICACY

It is one of the top five pharmaceutical companies in the world with healthcare sales of over $##. ## billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products.

  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Litigation And Patent
  • AstraZeneca PLC
  • Synergy Pharmaceuticals Inc - Opportunities
  • Company Overview

According to the International Foundation for Functional Gastrointestinal Disorders, IBS is the most common functional gastrointestinal disorder.

  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Company Financials
  • Synergy Pharmaceuticals, Inc.
  • Mechanism Of Action
  • MAY 02, 2001: ASTRAZENECA RECEIVES SIX MONTHS' MARKET EXCLUSIVITY FOR PRILOSEC

ASP-## is a selective COX ##(cyclooxygenases-##) inhibitor.

  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Litigation And Patent
  • AstraZeneca PLC
  • Ironwood Pharmaceuticals Inc, Major Products and Services
  • Ironwood Pharmaceuticals Inc - Opportunities

Linaclotide Delayed Release-## (DR##).

  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Company Financials
  • Ironwood Pharmaceuticals, Inc.
  • KBP-3571 - DRUG PROFILE
  • FEATURED NEWS & PRESS RELEASES

It is one of the world' s leading pharmaceutical companies with healthcare sales of $##. ## billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • Litigation And Patent
  • AstraZeneca PLC
  • NARONAPRIDE - DRUG PROFILE
  • REFLUX ESOPHAGITIS (GASTROESOPHAGEAL REFLUX DISEASE) - PIPELINE BY JEIL PHARMACEUTICAL CO LTD, H2 2017

Patients were randomly assigned to one of two arms - one arm received Insegia alone, the other arm received placebo.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Product Initiative
  • RENZAPRIDE - DRUG PROFILE

The trial demonstrated that RM-## significantly accelerates early gastric emptying and reduces upper gastrointestinal (GI) symptoms in type ## diabetic patients with diabetic gastroparesis.

  • Diabetes
  • Gastrointestinal Drug
  • United States
  • Product Initiative
  • Evoke Pharma, Inc.
  • REDHILL BIOPHARMA LTD - OPPORTUNITIES
  • NOV 06, 2017: REDHILL BIOPHARMA ANNOUNCES ENTERAGAM POSTER PRESENTATION AT THE ISPOR 20TH ANNUAL EUROPEAN CONGRESS

The agenda of the Meeting shall be as follows: ##.

  • Biopharmaceutical
  • Gastrointestinal Drug
  • United States
  • Company Financials
  • RedHill Biopharma Ltd.

It is one of the world' s leading pharmaceutical companies with healthcare sales of $##. ## billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products.

  • Gastrointestinal Drug
  • United States
  • Litigation And Patent
  • Product Initiative
  • AstraZeneca PLC
  • RECCE LTD
  • FEATURED NEWS & PRESS RELEASES

IBS is one of the most common gastrointestinal disorders.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • Company Operations
  • RedHill Biopharma Ltd.
  • Official Title
  • Clinical Trial profile. 145 Trial Title

The prominent features of this report are - ##.

  • Gastrointestinal Drug
  • Opioid
  • Pharmaceutical
  • World
  • Product Initiative
  • Clinical Trial profile. 144 Trial Title
  • Clinical Trial profile. 91 Trial Title

Boehringer Sohn AG & Co KG Phase IV Phase III Phase II/ III Phase II Phase I/ II Phase I TOTAL ## ## ## ## ## ## ## Tsumura & co ## ## ## ## ## ## ## BioGaia AB Echo Pharmaceuticals BV ## ## ## ## ## ## ## ## ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ##

  • Gastrointestinal Drug
  • Neurology
  • Therapy
  • World
  • Product Initiative

Patients were randomized ##:##:##:## to JZP-## ## mg, ## mg, ## mg and placebo.

  • Biopharmaceutical
  • Gastrointestinal Drug
  • Therapy
  • South Korea
  • SK Biopharmaceuticals Co., Ltd.
  • CHEMOTHERAPY INDUCED NAUSEA AND VOMITING - PIPELINE BY DAEWOONG PHARMACEUTICAL CO LTD, H1 2018
  • ROLAPITANT HYDROCHLORIDE - DRUG PROFILE

The Dronabinol XL AdVersa formulation is absorbed by the buccal mucosa thereby limiting exposure to the gastrointestinal tract.

  • Chemotherapy
  • Gastrointestinal Drug
  • United States
  • Product Initiative
  • Helsinn Group
  • TENAPANOR - DRUG PROFILE

Similarly, the Universities' portfolio in Preclinical and Discovery stages comprises ## and ## molecules, respectively.

  • Gastrointestinal Drug
  • United States
  • World
  • Product Initiative
  • Ardelyx, Inc.
  • 3.2 Key Trends & Developments
  • ARDELYX, Inc. Drugs Under Pipeline

These nerves control the functions of gastrointestinal tract.

  • Gastrointestinal Drug
  • United States
  • Forecast
  • Market Size
  • Sucampo Pharmaceuticals, Inc.
  • Clinical Trial profile. 25 Trial Title
  • Clinical Trial profile. 89 Trial Title

The prominent features of this report are - ##.

  • Gastrointestinal Drug
  • Neurology
  • Therapy
  • World
  • Product Initiative

" Dacomitinib is a more potent, second-generation EGFR inhibitor that shares the issue of increased side effects in the skin and gastrointestinal tract, like afatinib (Gilotrif).

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Therapy
  • United States
  • Product Initiative
  • APR 27, 2017: ALBIREO ANNOUNCES ELOBIXIBAT DATA FROM JAPAN TO BE PRESENTED AT DDW 2017
  • CJ-14199 - DRUG PROFILE

In April ##, 2016, Eisai' s gastrointestinal disease business and Ajinomoto Pharmaceuticals, with amino acids at its core, will be integrated and commence business as EA Pharma.

  • Gastrointestinal Drug
  • Japan
  • United States
  • World
  • Product Initiative
  • CJ-14199 - DRUG PROFILE

The most common adverse events occurring in Phase ## trials of SHP## were gastrointestinal in nature, predominantly diarrhea.

  • Gastrointestinal Drug
  • Japan
  • United States
  • World
  • Product Initiative